These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

233 related articles for article (PubMed ID: 11758580)

  • 21. Striking the right balance between innovation and drug price competition: putting the Hatch-Waxman Act into perspective.
    Deal JB
    Food Drug Law J; 1999; 54(2):185-6. PubMed ID: 11759712
    [No Abstract]   [Full Text] [Related]  

  • 22. Reach-through claims in the age of biotechnology.
    Kunin SG; Nagumo M; Stanton B; Therkorn LS; Walsh S
    Am Univ Law Rev; 2002 Apr; 51(4):609-38. PubMed ID: 12195606
    [No Abstract]   [Full Text] [Related]  

  • 23. Striking the right balance between innovation and drug price competition: understanding the Hatch-Waxman Act--an introduction of speakers.
    Rea TS
    Food Drug Law J; 1999; 54(2):223-5. PubMed ID: 11759713
    [No Abstract]   [Full Text] [Related]  

  • 24. Intellectual property. U.S. patent reform begins long journey through Congress.
    Kintisch E
    Science; 2005 Jun; 308(5729):1725-6. PubMed ID: 15961638
    [No Abstract]   [Full Text] [Related]  

  • 25. The market for follow-on biologics: how will it evolve?
    Grabowski H; Cockburn I; Long G
    Health Aff (Millwood); 2006; 25(5):1291-301. PubMed ID: 16966725
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Is Noerr-Pennington immunity still a viable defense against antitrust claims arising from Hatch-Waxman litigation?
    Steinhauer EH
    Food Drug Law J; 2006; 61(4):679-700. PubMed ID: 17180769
    [No Abstract]   [Full Text] [Related]  

  • 27. Biogenerics standoff.
    Herrera S
    Nat Biotechnol; 2004 Nov; 22(11):1343-6. PubMed ID: 15529145
    [No Abstract]   [Full Text] [Related]  

  • 28. Reach-through claims for drug target patents: Rx for pharmaceutical policy.
    Bohrer RA
    Nat Biotechnol; 2008 Jan; 26(1):55-6. PubMed ID: 18183015
    [No Abstract]   [Full Text] [Related]  

  • 29. Enforcing pharmaceutical and biotech patent rights in China.
    Zhang YP; Deng MM
    Nat Biotechnol; 2008 Nov; 26(11):1235-40. PubMed ID: 18997760
    [No Abstract]   [Full Text] [Related]  

  • 30. Robert Stoll. Interview by Charlotte Harrison.
    Stoll R
    Nat Rev Drug Discov; 2009 Dec; 8(12):926. PubMed ID: 19949397
    [No Abstract]   [Full Text] [Related]  

  • 31. The balance between innovation and competition: the Hatch-Waxman Act, the 2003 Amendments, and beyond.
    Kelly C
    Food Drug Law J; 2011; 66(3):417-78, iii. PubMed ID: 24505856
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Judicial developments in the US Hatch-Waxman infringement safe harbor.
    Swirnoff AH; Becker DM
    Expert Opin Ther Pat; 2010 Apr; 20(4):451-8. PubMed ID: 20302449
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Implications of
    Carson P; Cade A
    Pharm Pat Anal; 2019 May; 8(3):65-70. PubMed ID: 31179899
    [No Abstract]   [Full Text] [Related]  

  • 34. Proposed changes to patent code loom over biotech industry.
    Coombs A
    Nat Biotechnol; 2007 Dec; 25(12):1333-4. PubMed ID: 18066010
    [No Abstract]   [Full Text] [Related]  

  • 35. Cabilly patent finale.
    Waltz E
    Nat Biotechnol; 2008 Aug; 26(8):846. PubMed ID: 18688222
    [No Abstract]   [Full Text] [Related]  

  • 36. Biotech patenting slows in 2004.
    Lawrence S
    Nat Biotechnol; 2005 Oct; 23(10):1198. PubMed ID: 16211048
    [No Abstract]   [Full Text] [Related]  

  • 37. A brief history of 180-day exclusivity under the Hatch-Waxman Amendments to the Federal Food, Drug, and Cosmetic Act.
    Lietzan EK
    Food Drug Law J; 2004; 59(2):287-323. PubMed ID: 15298013
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Drug costs threaten patent protection.
    Cimons M
    Nat Med; 2003 Jan; 9(1):9. PubMed ID: 12514706
    [No Abstract]   [Full Text] [Related]  

  • 39. A precarious balancing act--the role of the FDA as protector of public health and industry wealth.
    McCabe AR
    Suffolk Univ Law Rev; 2003; 36(3):787-819. PubMed ID: 16493844
    [No Abstract]   [Full Text] [Related]  

  • 40. Razing the tollbooths. A call for restricting patents on basic biomedical research.
    Stix G
    Sci Am; 2003 Apr; 288(4):37. PubMed ID: 12661312
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.